Nalmefene for alcohol dependence: a NICE decision?
作者： Florian Naudet , Niamh Fitzgerald , Alain Braillon
DOI: 10.1016/S2215-0366(16)30356-X
关键词: Narcotic antagonists 、 Psychiatry 、 Naltrexone 、 Nice 、 Medicine 、 Alcohol dependence 、 Nalmefene
摘要:
sci-hub.se 参考文章(5)
D. Spence, Bad medicine: nalmefene in alcohol misuse. BMJ. ,vol. 348, ,(2014) , 10.1136/BMJ.G1531
A. Braillon, Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency BMJ. ,vol. 348, ,(2014) , 10.1136/BMJ.G2017
Matt Stevenson, Abdullah Pandor, John W. Stevens, Andrew Rawdin, Peter Rice, Jez Thompson, Marsha Y. Morgan, Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. ,vol. 33, pp. 833- 847 ,(2015) , 10.1007/S40273-015-0272-0
Clément Palpacuer, Bruno Laviolle, Rémy Boussageon, Jean Michel Reymann, Eric Bellissant, Florian Naudet, Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials PLOS Medicine. ,vol. 12, pp. e1001924- ,(2015) , 10.1371/JOURNAL.PMED.1001924
Niamh Fitzgerald, Kathryn Angus, Andrew Elders, Marisa Andrade, Duncan Raistrick, Nick Heather, Jim McCambridge, Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers Addiction. ,vol. 111, pp. 1477- 1487 ,(2016) , 10.1111/ADD.13438